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Abstract
Background: The cellular proteins Pat1p, Lsm1p, and Dhh1p are required for the replication of
some positive-strand viruses and therefore are potential targets for new antiviral drugs. To
prioritize host targets for antiviral drug screening a comparative metabolome analysis in
Saccharomyces cerevisiae reference strain BY4742 Matα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 and deletion
strains pat1Δ, lsm1Δ and dhh1Δ was performed.
Results: GC/MS analysis permitted the quantification of 47 polar metabolites and the identification
of 41 of them. Metabolites with significant variation between the strains were identified using partial
least squares to latent structures discriminate analysis (PLS-DA). The analysis revealed least
differences of pat1Δ to the reference strain as characterized by Euclidian distance of normalized
peak areas. The growth rate and specific production rates of ethanol and glycerol were also most
similar with this strain.
Conclusion: From these results we hypothesize that the human analog of yeast Pat1p is most
likely the best drug target candidate.
Background
Viruses continue to threaten human health. Well known
examples are the human immunodeficiency virus (HIV)
and the human hepatitis C virus (HCV) that have world-
wide infected around 40 and 170 million people, respec-
tively. While the former slowly destroys the immune
system of its host resulting in acquired immunodeficiency
and death due to the uncontrolled expansion of oppor-
tunistic infections, the latter, when becoming a chronic
infection, leads to liver cell destruction and after decades
to cirrhosis and possibly liver cell carcinoma. Even more
frightening can be viruses that have a much faster disease
course like some influenza strains, the SARS corona virus
and hemorrhagic fever viruses which can kill their hosts in
Published: 30 January 2009
Microbial Cell Factories 2009, 8:12 doi:10.1186/1475-2859-8-12
Received: 13 October 2008
Accepted: 30 January 2009
This article is available from: http://www.microbialcellfactories.com/content/8/1/12
© 2009 Schneider et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
Page 2 of 14
(page number not for citation purposes)
the order of days and weeks rather than several years.
Without having efficient vaccines available, the best at
hand to combat these threads are antiviral drugs. But there
are major limitations. For many of the viruses, especially
for the novel emerging viruses, there are no or only lim-
ited options for antiviral therapy. Furthermore, as most of
the antivirals are specifically targeting individual viral pro-
teins and, on the other hand, viruses most frequently
exhibit high replication error rates combined with a rapid
turnover of large populations, the selection of drug resist-
ant strains within an infected host is common. While this
problem can in part be solved by combining drugs with
different target specificities, a setback is the increased side
effects inherent to multi-drug intake [1].
The fast developing omics-technologies in the last few
years have witnessed a remarkable increase in our under-
standing of how complex cell systems are regulated at the
level of their genes, transcripts and proteins. Such types of
studies are now opening up a new era in antiviral drug
research [1]. Due to its genetic tractability and the new
technological platforms and tools recently created, global
studies in the yeast Saccharomyces cerevisiae have been at
the forefront of such technical advances [2]. Moreover,
since there is a notable gene homology between yeast and
human genes and a high conservation of fundamental
biochemical pathways, studies in yeast are helpful to dis-
cover fundamental cellular processes Remarkably, yeast-
based studies have provided main achievements in virus
research as well. These include, for example, the elucida-
tion of key processes in viral replication and its use in anti-
viral drug development [2]. For drug development high
throughput genomic analyses are performed to systemati-
cally screen the effect of a given drug on every gene. Such
analyses will promote the identification and understand-
ing of metabolic pathways and regulatory circuits
involved in the action of a drug. This information will also
provide a more detailed measure of toxicity and will there-
fore assist fundamentally the development of drug candi-
dates.
Large screens for host factor requirements of different
viruses have recently been completed demonstrating the
intimate and complex dependence of virus expansion on
cellular factors [3-6]. By targeting these so-called virus
dependency factors of the host cell by drugs, virus multi-
plication might not only be inhibited but in addition
might restrict the rapid generation of resistance. Further-
more, as groups of viruses share common replication
strategies and common host factor requirements, it might
become possible to even inhibit multiple viruses with a
single agent [1]. For example, some of the factors required
for the replication of model viruses in yeast are also
required for the replication of human viruses in human
cells [4,6,7] While this gives exciting future perspectives,
the present challenge is how to prioritize among the many
virus dependency factors experimentally determined.
BMV belongs to the family of alpha viruses which include
a number of plant, animal and also human positive strand
RNA viruses which exhibit common replication mecha-
nisms. In our previous work, we have shown that the pro-
teins Pat1p, Lsm1p-7p and Dhh1p that form a complex
essentially involved in the host deadenylation-dependent
mRNA decapping are required for BMV replication in
yeast. Deletion of PAT1, LSM1 or DHH1 genes led to a
comparable and dramatic inhibition of viral replication
[8]. Homologues of these factors are also found in human
and thus could serve as potential antiviral drug targets for
human positive-strand RNA viruses such as the Hepatitis
C virus [7,9-11].
Antiviral drugs should not only inhibit virus expansion
but also be non-toxic for the infected cells and the host.
One would expect the latter condition to be best fulfilled
if the change in cellular viability characteristics would be
minimal. Growth rate or even respiration are relevant pri-
mary characteristics [12]. Even more relevant are meta-
bolic flux distributions [13] but the presumably most
sensitive and most comprehensive indicator of such
changes is the cellular metabolome [14]. Any modifica-
tion on the level of DNA, RNA or proteins is expected to
be further manifested in metabolite level changes. The
scope of this work is to study the effect of the deletion of
PAT1, LSM1 and DHH1 on central metabolites in S. cere-
visiae  and to estimate the adverse effects on the host
organism and its metabolism by quantitatively comparing
their metabolomes. We found that the levels of metabo-
lites differed clearly between the reference strain S. cerevi-
siae  BY4742 and the deletion strains pat1Δ, lsm1Δ  and
dhh1Δ. PAT1 gene deletion resulted in the smallest devia-
tion from reference cells. This seems therefore the most
promising target with respect to host cell toxicity. High
throughput drug screening approaches should therefore
focus on the human analogue of PAT1.
Results
Physiological growth characterization
Measured growth characteristics of studied yeast strains
are summarized in Table 1. These are specific growth rate,
μ, the specific glucose uptake rate, qglucose, the specific
glycerol production rate, qglycerol, and the specific ethanol
production rate, qethanol. The specific growth rate of pat1Δ,
0.22 h-1, was quite similar to that of the reference strain,
0.28 h-1, whereas dhh1Δ, 0.16 h-1, and lsm1Δ, 0.15 h-1,
grew clearly slower. The specific glucose uptake rates of
pat1Δ and dhh1Δ, 2.00 ± 0.11 g g-1 CDW h-1 and 2.10 ±
0.10 g g-1 CDW h-1, were quite similar but differed signif-
icantly compared to the reference strain, 2.45 ± 0.13 g g-1
CDW h-1, and lsm1Δ, 1.67 ± 0.10 g g-1 CDW h-1. Consider-Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
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ing standard deviations specific glycerol production rates
were similar for the reference strain and the deletion
strains pat1Δ and dhh1Δ with 0.22 ± 0.03 g g-1 CDW h-1,
0.15 ± 0.03 g g-1 CDW h-1 and 0.18 ± 0.02 g g-1 CDW h-1.
The specific glycerol production rate of 0.10 ± 0.02 g g-1
CDW h-1 for the lsm1Δ strain was clearly lower. The spe-
cific ethanol production rate of 1.05 ± 0.05 g g-1 CDW h-1
for the reference strain was higher than for the deletion
strains pat1Δ and dhh1Δ with 0.72 ± 0.04 g g-1 CDW h-1
and 0.83 ± 0.04 g g-1 CDW h-1. The specific ethanol pro-
duction rate of the lsm1Δ mutant was lowest, 0.60 ± 0.03
g g-1 CDW h-1. Based on these results the deletion of the
PAT1 and DHH1 genes seem to have the least influence
on the metabolism of the cell. A clear prioritization is,
however not possible only considering these data. Gener-
ally, the specific uptake and production rates were propor-
tional to the specific growth rate μmax as described earlier
[12] which holds for the reference strain, pat1Δ and lsm1Δ.
The specific rates for dhh1Δ were slightly higher compared
to pat1Δ.
Metabolite identification and quantification
A typical GC/MS chromatogram of intracellular metabo-
lites of S. cerevisiae BY4742 pat1Δ is depicted in Figure 1.
This figure shows that most of the identified metabolites
were in the low abundance region of the chromatogram.
Most of the high abundant peaks are substances derived
from column bleeding or the derivatization reagent. Of
the detected 47 metabolites 41 were identified using their
fragmentation pattern and retention index. Among the
identified metabolites were proteinogenic and non-pro-
teinogenic amino acids, organic acids, bases, sugars, phos-
phorylated sugars and several unidentified metabolites.
Another seven metabolites could not be identified but
were also included in the metabolite profiling of the three
strains since they differed significantly in the investigated
strains. The identified metabolites are shown in Table 2.
Relative quantification was carried out using only charac-
teristic m/z values of these identified metabolites which
are also shown in Table 2. Compared to the use of the
total ion current for the calculation of relative signals this
resulted in a significant decrease of the signal-to-noise
ratio and allowed a precise quantification even in the
presence of co-eluting or incompletely separated metabo-
lites. This kind of normalization yielded more consistent
results compared to normalization to CDW or internal
standards and was therefore used for the comparison of
the four strains (Table 3). The resulting average error was
approximately 20% comparing six samples from each
strain. For checking the suitability of the chosen normali-
zation method, intracellular amino acid concentrations of
the same samples were determined by HPLC [15] and GC/
MS. A good correlation was found between normalized
peak areas and intracellular amino acid concentration as
depicted in Figure 2 for the amino acids phenylalanine,
aspartic acid and glycine.
Strain comparison using GC/MS
The three deletion strains pat1Δ, dhh1Δ and lsm1Δ and the
reference strain BY4742 were compared using relative
pool sizes of intracellular metabolites, characterized by
normalized peak areas, derived from GC/MS measure-
ments. Figure 3 compares the intracellular metabolite
pool sizes in the three deletion strains to the reference
strain BY4742. Metabolites on the straight line have the
same concentration in both strains.
Based on the normalized peak areas, the Euclidian dis-
tance between the three deletion strains and the reference
strain was calculated and used for characterizing similar-
ity. In this way we could estimate the influences of the
deletions of the PAT1, DHH1 and LSM1 genes on the cel-
lular metabolism. The comparison was made in three
steps and is presented in dendrograms (Figure 4). In a first
calculation the whole data set was used (Figure 4A). In a
second all metabolites usually not observed in human
that are indicated in Table 3 were used (Figure 4B).
Finally, also the essential amino acids that are not synthe-
sized by human were removed in a third analysis (Figure
4C). In all cases it is evident that the deletion of the PAT1
gene caused the smallest differences in the metabolite pat-
tern compared to the reference strain. Therefore, the
whole data set was used for further analysis. The deletion
Table 1: Specific rates during growth on glucose of the reference strain S. cerevisiae BY4742 and the used deletion strains pat1Δ, dhh1Δ 
and lsm1Δ.
specific rate BY4742 reference pat1Δ dhh1Δ lsm1Δ
μ [h-1] 0.28 ± 0.00 0.22 ± 0.00 0.16 ± 0.01 0.15 ± 0.00
qglucose [g glucose/(g CDW. h)] 2.45 ± 0.13 2.00 ± 0.11 2.10 ± 0.10 1.67 ± 0.10
qglycerol [g glycerol/(g CDW. h)] 0.22 ± 0.03 0.15 ± 0.03 0.18 ± 0.02 0.10 ± 0.02
qethanol [g ethanol/(g CDW. h)] 1.05 ± 0.05 0.72 ± 0.04 0.83 ± 0.04 0.60 ± 0.03
μ – specific growth rate. q – specific rate.Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
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of the genes DHH1 and LSM1 caused larger deviations.
This is in accordance with the specific growth rates of the
four strains describing the overall fitness of the cells.
Principal component analysis and strain separation
Principal component analysis (PCA) using normalized
peak areas from GC/MS analysis of the cell extracts reveals
clear separation of the four strains (WT, pat1Δ, lsm1Δ and
dhh1Δ). Figure 5 shows the corresponding scores plot. The
four strains form distinct clusters using two parallel cul-
tures and three sampling times each. These results confirm
that cells were in true exponential growth and therefore
constant concentrations of intracellular metabolites could
be assumed during the entire sampling period. At the dif-
ferent sampling times biomass concentration was varying
between 0.73 – 1.44 g CDW l-1, but did obviously not
cause significant disturbances. These results also indicate
the applicability of the chosen normalization procedure
since resulting PLS scores are randomly distributed within
their specific cluster. Figure 5 again shows that metabo-
lites measured in the pat1Δ deletion strain are least deviat-
ing from those in the reference strain. The two deletion
GC/MS spectrum of a S. cerevisiae  BY4742 pat1Δ cell extract Figure 1
GC/MS spectrum of a S. cerevisiae  BY4742 pat1Δ cell extract. The numerical labels of the identified compounds are 
specified in Table 2. (A) whole intensity rage, (B) 0 -1% of abundance range.
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strains lsm1Δ and dhh1Δ are obviously more distant agree-
ing with the Euclidian distance calculations depicted in
Figure 4.
Identification of statistically significant metabolites using 
PLS-DA
The selection of statistically significant metabolites was
made using loading plots for each of the three compari-
sons (Figure 6). All metabolites whose confidence inter-
vals do not include zero were assumed statistically
significant. Strain comparison was carried out using only
these metabolites. The concentration differences are pre-
sented in a heat plot (Figure 7).
The most significant differences between the reference
strain BY4742 and the three deletion strains was the accu-
mulation of intracellular trehalose. Intracellular pools
were clearly increased in the three deletion strains. The
highest concentration was found in the lsm1Δ strain (200
times the concentration in the reference strain) while the
intracellular pools of the two strains pat1Δ  and dhh1Δ
were approximately 25 times higher compared to the ref-
erence strain pool size of intracellular trehalose. Increased
intracellular trehalose levels were observed when apply-
ing a heat shock or oxidative stress to the cells [16]. The
measured TCA cycle metabolites succinic acid, malic acid,
fumaric acid, α-ketoglutaric acid and citric acid were more
accumulated in the deletion strains. Especially malic acid
was concentrated 2 times, 3 times and 6 times higher in
the strains pat1Δ, dhh1Δ and lsm1Δ compared to the refer-
ence strain. The citric acid pool size of the deletion strain
dhh1Δ was 5 times higher than the corresponding refer-
ence strain pool size. The urea cycle metabolites ornithine
and arginine were slightly higher concentrated in the dele-
tion strains pat1Δ and dhh1Δ but levels are decreased in
the lsm1Δ strain. Fumaric acid, which is also produced via
the urea cycle, showed a higher abundance in the lsm1
deletion strain compared to the reference strain and pat1Δ
and dhh1Δ indicating that the urea cycle was affected in
another way in this strain.
Intracellular amino acid concentrations were always
higher in the deletion strains or not significantly changed.
The only exception was arginine in the lsm1  deletion
strain as discussed above. A comparison of the reference
strain S. cerevisiae BY4742 with the non-auxotrophic wild
type S. cerevisiae ATCC 32167 revealed that the intracellu-
lar concentrations of leucine, histidine and lysine were
always higher than in the non-auxotrophic wild type
strain. Here the concentration of leucine, histidine and
lysine of strain BY4742 were 13.1, 39.2 and 93.9 μmol/g
CDW. In the wild type strain S. cerevisiae ATCC 32167 all
other intracellular amino acid concentrations were in the
same range as in S. cerevisiae BY4742, except the three
amino acids supplied in the medium with concentrations
Table 2: Metabolites identified in the cell extracts of BY4742 and 
the used deletion mutants using the software AMDIS v2.0 and a 
TMS library.
metabolite peak number m/z #TMS/MeOx
glycine 1 102 2
alanine 2 116 2
pyruvic acid 3 174 1/MeOx
lactic acid 4 117 2
valine 5 144 2
u. m. #1 6 110 n.k.1
ethanolamine 7 174 2
glycerol 8 218 3
isoleucine/leucine 9 158 2
succinic acid 10 247 2
uracil 11 241 2
fumaric acid 12 245 2
serine 13 204 3
threonine 14 218 3
homoserine 15 218 3
malic aicd 16 233 3
u. m. #2 17 188 n.k.1
erythritol 18 217 4
aspartic acid 19 218 3
u. m. #6 20 258 n.k.1
cytosine 21 254 2
α-ketoglutaric acid 22 198 2/MeOx
glutamic acid 23 246 3
phenylalanine 24 192 2
ribose 25 217 4/MeOx
asparagine 26 231 3
2-aminoadipic acid 27 260 3
orotic acid 28 254 3
glycerol-1-phosphate 29 370 4
glutamine 30 156 3
N-acetyl-glutamic acid 31 216 2
u. m. #3 32 257 n.k.1
citric acid 33 273 4
ornithine 34 258 4
arginine 35 256 5
adenine 36 279 2
lysine 37 230 4
histidine 38 356 3
manitol 39 307 6
tyrosine 40 218 3
u. m. #4 41 258 n.k.1
inositol 42 305 6
xylulose-5-phosphate 43 315 5/MeOx
glucose-6-phosphate 44 387 6/MeOx
u. m. #7 45 387 n.k.1
u. m. #5 46 204 n.k.1
trehalose 47 361 8
Peak numbers correspond to the labelling of the data points in Figure 
2. #TMS denotes tert-methyl-silyl residues in the detected analyte 
originating from derivatization, MeOx denotes methoxymation of the 
metabolite. 1n.k., not known; u.m., unknown metabolite.Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
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0.9, 3.4 and 9.5 μmol/g CDW, respectively. Their concen-
trations were approximately 10 times higher compared to
S. cerevisiae ATCC 32167. This difference can be explained
by the feeding of these essential amino acids in excess to
the S. cerevisiae BY4742 and mutant cultures.
Discussion
Previously it was shown that the proteins Pat1p, Lsm1p-
7p and Dhh1p are required for BMV replication in yeast
[8]. Homologues of these factors are also found in
humans and can serve as potential antiviral drug targets
for human positive strand RNA viruses like Hepatitis C
Table 3: Peak areas of detected metabolites normalized to total peak area in BY4742 and the three deletion strains pat1Δ, dhh1Δ and 
lsm1Δ using GC/MS.
BY4742 pat1Δ dhh1Δ lsm1Δ
metabolite mean s. d. mean s. d. mean s. d. mean s. d.
glycine 4.67E-05 1.10E-05 6.07E-05 1.12E-05 5.68E-05 4.58E-06 1.97E-04 2.26E-05
alanine 1.28E-04 2.68E-05 1.34E-04 3.07E-05 2.08E-04 3.27E-05 1.06E-03 1.71E-04
pyruvic acid 1.02E-05 5.52E-06 9.87E-06 2.62E-06 6.24E-06 8.64E-07 4.59E-06 6.12E-07
lactic acid 1.65E-05 1.72E-06 1.22E-05 2.44E-06 7.95E-06 1.47E-06 7.67E-06 2.35E-06
valineE 4.73E-05 8.82E-06 6.02E-05 9.70E-06 4.91E-05 7.67E-06 1.80E-04 2.54E-05
u. m. #1 2.25E-05 5.10E-06 3.33E-05 6.92E-06 4.38E-05 1.92E-05 9.97E-06 2.39E-06
ethanolamine 8.47E-06 3.27E-06 6.76E-06 1.37E-06 1.14E-05 1.74E-06 2.11E-05 6.15E-06
glycerol 3.38E-04 5.49E-05 3.36E-04 2.36E-05 6.98E-04 6.75E-05 5.96E-04 1.01E-04
isoleucine/leucineE 5.32E-06 2.21E-06 5.08E-06 1.04E-06 7.69E-06 5.53E-07 2.22E-05 3.13E-06
succinic acid 4.71E-06 1.74E-06 2.59E-06 1.08E-07 4.65E-06 2.64E-07 1.01E-05 1.09E-06
uracil 1.55E-05 3.05E-06 1.72E-05 3.08E-06 1.70E-05 5.16E-06 1.99E-05 2.05E-06
fumaric acid 4.56E-06 1.43E-06 6.06E-06 9.78E-07 8.08E-06 3.39E-07 1.78E-05 2.32E-06
serine 2.17E-05 5.77E-06 2.10E-05 2.57E-06 3.94E-05 3.32E-06 3.45E-05 6.43E-06
threonineE 1.94E-05 4.14E-06 2.19E-05 2.94E-06 3.70E-05 3.35E-06 5.99E-05 5.37E-06
homoserineN 9.32E-06 1.60E-06 9.77E-06 1.52E-06 1.71E-05 1.15E-06 2.50E-05 2.18E-06
malic acid 3.98E-06 9.76E-07 7.88E-06 9.28E-07 1.23E-05 8.03E-07 2.30E-05 3.55E-06
u. m. #2 2.41E-06 3.99E-07 2.50E-06 4.32E-07 3.69E-06 2.40E-07 4.60E-06 4.01E-07
ErythritolN 2.13E-06 2.67E-07 1.75E-06 2.73E-07 n.d.1 n.d.1 n.d.1 n.d.1
aspartate 2.39E-05 3.44E-06 3.89E-05 3.18E-06 1.29E-04 1.20E-05 1.03E-04 1.43E-05
u. m. #6 7.99E-05 1.28E-05 7.55E-05 1.50E-05 4.56E-05 2.41E-06 4.82E-05 9.02E-06
cytosine 7.49E-06 1.03E-06 6.97E-06 1.21E-06 5.64E-06 1.90E-06 5.94E-06 1.05E-06
α-ketoglutaric acid 3.89E-07 1.84E-07 6.66E-07 9.73E-08 4.56E-07 8.42E-08 n.d.1 n.d.1
glutamate 6.97E-05 1.84E-05 1.45E-04 1.84E-05 1.33E-04 2.12E-05 8.20E-05 1.03E-05
phenylalanineE 2.56E-06 6.33E-07 3.94E-06 4.11E-07 4.88E-06 7.75E-07 3.28E-06 4.78E-07
ribose 1.50E-06 4.90E-07 8.37E-07 1.52E-07 4.72E-07 7.98E-08 5.02E-07 1.66E-07
asparagine 1.79E-06 6.49E-07 2.34E-06 3.99E-07 3.91E-06 1.09E-06 2.37E-06 7.65E-07
2-aminoadipic acid 4.03E-06 1.22E-06 2.32E-06 3.72E-07 8.49E-07 1.57E-07 4.12E-06 4.93E-07
orotic acid 6.56E-05 2.11E-05 3.38E-05 2.74E-06 1.55E-05 2.70E-06 7.66E-05 1.05E-05
glycerol-1-phosphate 5.65E-07 1.05E-07 6.80E-07 4.76E-08 5.17E-07 1.10E-07 n.d.1 n.d.1
glutamine 1.86E-06 5.48E-07 4.54E-06 3.26E-06 1.46E-05 4.06E-06 4.19E-06 4.66E-06
N-acetyl-glutamic acid 5.62E-07 1.34E-07 1.63E-06 3.29E-07 5.72E-07 9.51E-08 n.d.1 n.d.1
u. m. #3 1.06E-05 7.65E-06 8.19E-06 1.98E-06 1.88E-06 1.75E-07 1.31E-05 1.94E-06
citric acid 9.43E-06 1.82E-06 1.47E-05 1.51E-06 4.79E-04 7.40E-05 1.28E-05 3.12E-06
ornithine 3.69E-06 1.17E-06 1.17E-05 1.40E-06 1.40E-05 2.94E-06 1.69E-06 3.42E-07
arginine 4.17E-06 1.10E-06 1.19E-05 1.88E-06 6.33E-06 1.33E-06 8.16E-07 4.37E-07
adenine 3.78E-06 8.22E-07 3.84E-06 9.41E-07 3.86E-06 1.24E-06 4.82E-06 7.76E-07
lysineE 1.52E-04 4.67E-05 2.16E-04 1.11E-05 4.15E-04 3.30E-05 4.44E-04 5.42E-05
histidinEe 1.36E-05 1.63E-06 1.93E-05 8.38E-06 2.83E-05 3.25E-06 1.23E-05 8.86E-07
mannitolN 4.96E-07 7.11E-08 1.03E-06 1.34E-07 6.30E-07 9.23E-08 9.67E-07 1.55E-07
tyrosineE 8.22E-06 3.02E-06 2.14E-05 1.96E-06 1.93E-05 1.76E-06 1.72E-05 1.35E-06
u. m. #4 1.74E-06 3.53E-07 8.75E-07 1.18E-07 9.58E-07 1.96E-08 1.15E-06 2.03E-07
inositol 4.81E-05 9.72E-06 4.23E-05 3.34E-06 3.28E-05 1.83E-06 3.41E-05 3.38E-06
xylulose-5-phosphate 3.15E-06 1.36E-06 1.12E-06 1.55E-07 1.22E-06 2.81E-07 7.68E-07 6.53E-08
glucose-6-phosphate 6.96E-06 1.59E-06 5.92E-06 1.56E-06 2.11E-06 4.92E-07 1.54E-06 1.15E-06
u. m. #7 3.44E-06 5.64E-07 1.70E-06 6.00E-07 3.39E-06 1.12E-06 4.58E-06 5.05E-07
u. m. #5 2.56E-06 3.60E-07 2.73E-06 4.09E-07 1.69E-06 2.72E-07 1.75E-06 5.30E-07
trehaloseN 5.08E-06 9.10E-07 1.87E-04 5.06E-05 9.54E-05 2.70E-05 9.61E-04 2.13E-04
E indicates essential amino acids; N indicates metabolites usually not observed in human cells.Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
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virus [7,9-11]. To analyze which of the proteins is the
most promising target for a new inhibitory drug, it is of
primary importance to show the efficacy of the target inhi-
bition but at the same time it is equally important to find
out which of the potential targets would be least harmful
to the host organism. Such studies are difficult in human
cells and yeast seems suitable as model organism to prior-
itize amongst the potential targets. It is not a priori clear
which parameter would be most reasonable to measure
deletion effects most sensitively. We think however that
metabolome analysis is a most ideal candidate to describe
the phenotype of a cell [17-19] since it reflects effects on
the gene, RNA and protein levels comprehensively.
All three genes, PAT1, LSM1 and DHH1 essential for virus
propagation are dispensable for yeast growth. However,
the quantitative effects of the individual deletions on
physiological parameters as growth and substrate con-
sumption rates and intracellular metabolite levels were
different. In our study we could identify 41 intracellular
metabolites and 6 metabolites of unknown chemical
structure in polar extracts of S. cerevisiae using GC/MS cov-
ering nearly all parts of central metabolism. The average
variation of intracellular metabolite concentrations of the
six independent samples of one single strain was around
20%. The variation in the analysis of polar leaf extracts of
Arabidopsis thaliana resulted in 101 identified metabolites
and 113 of unknown chemical structure and a biological
variation of 35% in average [20]. Strelkov et al. [21] iden-
tified 88 intracellular metabolites in the polar extracts of
Corynebacterium glutamicum. More metabolites could be
identified with less stringent identification criteria; how-
ever here we used the standard identification criteria of
the AMDIS software. As Figure 2 shows, there are a lot
more compounds visible in the chromatogram than iden-
tified and used for strain comparison in this work. Using
less stringent identification rules resulted in the identifica-
tion of 39 additional metabolites which were, however,
not used for strain comparison. Most importantly, this
study showed clear differences on the intracellular metab-
olome changes between the different gene deletion
strains. Intracellular metabolite levels of all three deletion
strains, pat1Δ, lsm1Δ and dhh1Δ differed from those of the
reference strain S. cerevisiae BY4742. It was, however,
found that the deletion of PAT1 showed the least differ-
ences to the reference strain. Some of the metabolites
found (Table 3) are usually not observed in human, oth-
ers are essential amino acids that are not synthesized by
human. It is interesting to see that metabolome differ-
ences were similar with and without these metabolites.
This indicates a certain robustness of the method. The
most pronounced non-human metabolite, trehalose,
may, however, be replaced by glycogen in human. The
other non-human metabolites, erythritol, mannitol and
homoserine are changed only little. Intracellular concen-
trations of amino acids essential in human are changed
significantly in yeast but this did not have any significant
effect on the overall analysis. The metabolome results are
supported by the fact that the measured specific growth
rates of the pat1Δ strain and the reference strain were most
similar. In general it can however be expected that metab-
olome analysis is much more sensitive than mere growth
rate determination and will, together with genomic, tran-
scriptomics and proteomic assays, greatly enhance our
understanding of mechanisms of drug effect and of
adverse drug reactions [14].
Conclusion
In this work the intracellular metabolome of a series of S.
cerevisiae strains with deletions of genes coding for the cel-
lular proteins Pat1p, Lsm1p, and Dhh1p was analyzed.
These proteins are required for the replication of some
Comparison of intracellular amino acid concentrations determined by HPLC using the method of Hans et al. (2001) in μmol/g  CDW and normalized peak areas for the amino acids (A) aspartic acid, (B) glycine and (C) phenylalanine determined by GC/MS Figure 2
Comparison of intracellular amino acid concentrations determined by HPLC using the method of Hans et al. 
(2001) in μmol/g CDW and normalized peak areas for the amino acids (A) aspartic acid, (B) glycine and (C) 
phenylalanine determined by GC/MS.
2468 1 0 1 2 1 4 1 6
4
8
12
16
20
24
R=0.948
glycine
10 20 30 40 50 60
2
4
6
8
10
12
14 aspartic acid
R=0.956
n
o
r
m
a
l
i
z
e
d
 
p
e
a
k
 
a
r
e
a
intracellular concetration [μmol/g CDW]
0,4 0,6 0,8 1,0 1,2 1,4 1,6
2,5
3,0
3,5
4,0
4,5
5,0
phenylalanine
R=0.981
A B C
x 10
-5
x 10
-5
n
o
r
m
a
l
i
z
e
d
 
p
e
a
k
 
a
r
e
a
intracellular concetration [μmol/g CDW]
n
o
r
m
a
l
i
z
e
d
 
p
e
a
k
 
a
r
e
a
intracellular concetration [μmol/g CDW]
x 10
-6
 Microbial Cell Factories 2009, 8:12 http://www.microbialcellfactories.com/content/8/1/12
Page 8 of 14
(page number not for citation purposes)
Comparison of intracellular metabolites of S. cerevisiae strains analyzed by GC/MS using normalized peak areas, Ii Figure 3
Comparison of intracellular metabolites of S. cerevisiae strains analyzed by GC/MS using normalized peak 
areas, Ii. (A) dhh1Δ mutant versus reference BY4742, (B) pat1Δ versus reference BY4742, (C) lsm1Δ versus reference 
BY4742. The solid line indicates identical concentrations in both strains. Data points denote the mean of the normalized areas 
taken from six independent samples. Error bars in both directions indicate the corresponding standard deviations. The numer-
ical labels of the single metabolites are defined in Table 2.
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positive-strand viruses and are therefore potential targets
for new antiviral drugs. In our attempt to prioritize host
targets for antiviral drug screening we arrived at the con-
clusion that the human gene corresponding to Pat1p
seems the most promising therapeutic target of the
selected proteins essential for the development of antivi-
ral drugs against positive-strand RNA viruses. The results
presented here also show that intracellular metabolome
analysis is a sensitive and powerful tool to tackle prob-
lems of this type.
Methods
Organisms and cultivation
S. cerevisiae ATCC 32167 was purchased from ATCC. S.
cerevisiae deletion mutants with the parental phenotype
BY4742 Matα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 were obtained
from Open Biosystems (Heidelberg, Germany). The
derived yeast deletion mutants Δlsm1 Δpat1 and Δdhh1 are
resistant to the antibiotic geneticin and exhibit auxothro-
phies for histidine, leucine, lysine and uracil. Yeast cells
were grown on YPD-agar plates (10 g/l yeast extract, 20 g/
l peptone, 20 g/l glucose) containing 200 mg/l Geneticin.
Cultivation was carried out first on complex YPD-medium
at 30°C followed by a second pre-culture on defined syn-
thetic medium containing (NH)4HPO4 1 g/l, (NH)4SO4
8.75 g/l, MgSO4·7 H2O 1 g/l, citric acid 1.1 g/l, CaCl2·2
H2O 0.15 g/l, glucose 20 g/l, 0.5 M Na-phosphate buffer
(pH 6.0) 100 ml/l, 100× trace element solution 10 ml/l
and 100× vitamin solution 10 ml/l. Lysine, leucine (each
120 mg/l), histidine and uracil (each 80 mg/l) were added
from 100× stock solutions to allow growth of the deletion
mutants. 100× vitamin solution consists of myo-inositol
301.5 mg/l, Ca-panthotenate 150 mg/l, thiamin/HCl 30
mg/l, pyridoxine/HCl 7,5 mg/l and biotin 0,15 mg/l.
100× trace element solution consists of FeCl3·6 H2O 75
mg/l, MnSO4·H2O 53 mg/l, ZnSO4·7 H2O 45 mg/l and
CuSO4·5 H2O 12 mg/l [12]. The main culture was carried
out in defined synthetic medium using 1000 ml baffled
shake flasks. The same medium without additional amino
acids and uracil was also used for the cultivation of S. cer-
evisiae ATCC 32167 that is the wild type of the used refer-
ence strain BY4742.
For inter-strain comparison of intracellular metabolite
concentrations, two parallel cultures were grown, and
three samples were taken during the exponential growth
phase. Cells were harvested at optical densities between 2
and 3. Exponential growth was observed for at least 30
min after taking samples for metabolite extraction to
ensure that no changes in cell metabolism occurred, due
to substrate limitation effects.
Analytics
Cell dry weight (CDW) was determined gravimetrically
after washing cells twice with double distilled water. After
centrifugation (10 min, 8,000 × g, 4°C, Biofuge stratos,
Heraeus, Hanau, Germany) the drying was performed at
80°C until constant weight was observed. Optical density
(OD660 nm) was determined at 660 nm (Novaspec II, Phar-
macia Biotech, Freiburg, Germany). The linear correlation
between CDW and OD660 is CDW [g/l] = 0.51 [g/l]·OD660
nm. OD-CDW correlations of the four strains were identi-
cal.
Concentrations of extracellular glycerol, glucose and eth-
anol were determined by HPLC (Kroma System, Kontron
Instruments, Neufahrn, Germany) with an Aminex HPX-
87H column (300 × 7,8 mm; Bio-Rad, Hercules, USA) and
an isocratic flow of 0.5 ml/min 22 mM H2SO4 at 35°C.
Glucose and ethanol concentrations in the supernatant
Strain comparison based on intracellular metabolites extracted form S. cerevisiae BY4742 and the tree deletion strains pat1Δ,  dhh1Δ and lsm1Δ and analyzed using GC/MS Figure 4
Strain comparison based on intracellular metabolites extracted form S. cerevisiae BY4742 and the tree dele-
tion strains pat1Δ, dhh1Δ and lsm1Δ and analyzed using GC/MS. A – full data set; B – data without metabolites not 
observed in human as indicated in Table 3; C – same as B but with additional removal of essential amino acids that are not syn-
thesized in human. The distances between the four strains correspond to the Euclidian distance calculated by using the normal-
ized areas of the extracted metabolites of the four strains.
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were determined using enzymatic kits (Boehringer Man-
nheim, R-Biopharm GmbH, Darmstadt, Germany) in
addition to HPLC analysis. Intracellular amino acid con-
centrations were determined by HPLC using an OPA
method [22].
Quenching and metabolite extraction
For metabolome analysis three independent samples of
10 ml were drawn from each of the two cultures during
the exponential growth phase and transferred immedi-
ately under vigorous shaking to a 50 ml falcon tube, filled
with pre-cooled quenching solution (-40°C, 60% metha-
nol, 10 mM HEPES, pH 7.5). Separation of cells and
medium was performed by centrifugation (5 min, 8,000 ×
g, -19°C, Biofuge stratos, Heraeus, Hanau, Germany)
[23]. The temperature was always below -25°C during the
whole quenching process. After an additional washing
step the metabolite extraction was achieved by incubating
the pellet with 2 ml of boiling water for 15 min. Cell-
debris was separated by centrifugation (10 min, 1,500 × g,
4°C, Labofuge 400R, Heraeus, Hanau, Germany) and
extracted again with 750 μl chloroform (37°C, 10 min).
The two phases were combined and separated again by
centrifugation. The polar phase was further analyzed. The
sampling process until quenching was not oxygen limited.
This was ensured by measuring dissolved oxygen (DO)
concentration using an optical method [24]. DO concen-
trations were always above 30% of air saturation.
GC/MS analysis of intracellular metabolites
Prior to GC/MS analysis 100 μl of the cell extract was
lyophilized (Lyovac GT2, GEA Lyophil GmbH, Huerth,
Germany). The remaining powder was derivatised using
25 μl 20 g/l methoxylamine/HCl in pyridine for oxima-
tion (30 min, 80°C) followed by 50 μl N-methyl-N-tri-
methylsilyl-trifluoroacetamide (MSTFA) for silylation.
PCA scores plot based on normalised peak areas from GC/MS analysis of cell extracts and the four strains BY4742 (reference),  pat1Δ, dhh1Δ and lsm1Δ (each one n=6) Figure 5
PCA scores plot based on normalised peak areas from GC/MS analysis of cell extracts and the four strains 
BY4742 (reference), pat1Δ, dhh1Δ and lsm1Δ (each one n=6). Analysis was conducted using SIMCA-P+ 11.5 (Umet-
rics, Malmö, Sweden). Data were pareto scaled and the first two components were autofitted.
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Loading plots of PLS-DA analysis of (A) reference and pat1Δ, (B) reference and lsm1Δ and (C) reference and dhh1Δ (each one  n=6) cell extracts from GC/MS analysis using normalized peak areas Figure 6
Loading plots of PLS-DA analysis of (A) reference and pat1Δ, (B) reference and lsm1Δ and (C) reference and 
dhh1Δ (each one n=6) cell extracts from GC/MS analysis using normalized peak areas. Error-bars indicate jack-
knifed confidence intervals. Values below zero indicate a higher concentration compared to the reference strain. Values above 
zero denote lower concentrations compared to the reference strain. Data were pareto scaled and analysis was carried out 
using SIMCA-P+ 11.5 (Umetrics, Malmö, Sweden).
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Sample analysis was carried out on a HP6890 GC System
using a Mass Selective Detector 5973 (Agilent Technolo-
gies, Waldbronn, Germany). Full scan mass spectra were
acquired ranging from 30 to 600 amu using a scan rate of
9 scans/s. Separation was performed using a 60 m × 0.2
mm I.D. fused silica HP-5 ms column (Agilent Technolo-
gies, Waldbronn, Germany) and a helium carrier gas flow
rate of 0.7 ml/min. After 1 min at 70°C the temperature
was increased to 75°C (1°C/min) followed by a second
increase to 315°C (5°C/min) and finally to 340°C
(25°C/min). 1μl of derivatised sample was injected split-
less for 2 min using a PTV with a temperature gradient
from 75°C to 340°C with a rate of 360°C/min. injector.
Temperatures of ion source and transfer liner were 200°C
and 240°C. For electron impact ion generation a 70-eV
electron beam was used. Intracellular amino acid concen-
trations were determined by HPLC using the OPA method
[15].
Metabolite identification and deconvolution
Metabolite identification and signal deconvolution was
performed using the AMDIS software (version 2.64,
National Institute of Standards and Technology, Gaithers-
burg, USA) as well as the Enhanced ChemStation software
(Agilent Technologies, Waldbronn, Germany). Identifica-
tion of metabolites is based on the comparison of meas-
ured mass spectra and retention indices (RI) with in-
house library entries [25] of pure component mass spectra
and retention indices or the National Institute of Stand-
ards and Technology (NIST) library. Retention indices
Heat map of 47 metabolites that show statistically significant changes between the reference strain (n=6) and the three dele- tion strains pat1Δ, dhh1Δ and lsm1Δ (each one n=6) Figure 7
Heat map of 47 metabolites that show statistically significant changes between the reference strain (n=6) and 
the three deletion strains pat1Δ, dhh1Δ and lsm1Δ (each one n=6).  Red color denotes lower concentrations in the 
deletion strains; green color indicates higher  concentrations in the deletion strains. Statistically significant metabolites were 
identified  using the loading plots shown in Figure 6. G6P, glucose-6-phosphate; G1P, glycerol-1- phosphate; X5P, xylulose-5-
phosphate; u. m.; unknown metabolite; WT, reference strain BY4742. 
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were scaled using a standard of 33 hydrocarbons ranging
from C8 to C40. To determine the differences among the
reference and the deletion strains a relative quantification
is sufficient. Relative quantification of metabolites was
carried out using peak areas of characteristic m/z ratio
intensities of these metabolites that were normalized to
the integral of the total intensity over the whole chroma-
togram.
PLS modeling and PCA
To find statistically significant differences between the
metabolite profiles of the reference strain and the three
deletion strains, the partial least squares to latent struc-
tures (PLS) regression method was applied [26]. This is
commonly used in the analysis of data from multivariate
studies to find significant relationships between different
classes, here the reference strain and deletion strains. The
PLS estimation resulted in three sets of model parameters
each one comparing one of the deletion strains with the
reference strain. Calculation of the model parameters was
carried out using SIMCA-P 11.5+ (Umetrics, Malmö, Swe-
den). To reduce the impact of artifacts and noise during
the modeling process, pareto scaling was used for all vari-
ables. For data visualization and selection of interesting
metabolites loading plots with jack-knifed confidence
intervals were chosen as described by Wiklund et al. [27].
Euclidian distance
Euclidian distances between different strains were calcu-
lated using Matlab (version 7.2.0.232, The Math Works,
Inc., Boston, USA). The Euclidian distance d(x, y) between
two points x = (x1, x2,..., xn) and y = (y1, y2,..., yn) in a n-
dimensional space is defined as
For each knock-out strain the Euclidian distance to the ref-
erence strain was calculated and visualized in the form of
a dendrogram. Each vector includes the normalized areas
of the corresponding metabolites which are statistically
significant based on the PLS-DA (PLS-discriminant analy-
sis).
Chemicals
Peptone was obtained form Bacto (Sparks, USA). Yeast
Extract and nutrient agar were obtained from Difco
(Sparks, USA). MSTFA was obtained form Macherey-
Nagel (Düren, Germany). All other chemicals used were
of analytical grade and obtained either from Sigma-
Aldrich (St. Louis, USA) or Fluka (Buchs, Switzerland).
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